StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)

StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a report released on Wednesday morning. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Price Performance

Shares of NASDAQ:OPGN opened at $1.90 on Wednesday. The company’s fifty day moving average is $2.63 and its two-hundred day moving average is $4.05. OpGen has a 12-month low of $1.65 and a 12-month high of $38.40.

OpGen (NASDAQ:OPGN) last posted its quarterly earnings results on Monday, July 8th. The medical research company reported $0.21 earnings per share for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 997.34%. The firm had revenue of $0.17 million for the quarter.

Institutional Trading of OpGen

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp bought a new position in OpGen, Inc. (NASDAQ:OPGN) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen as of its most recent SEC filing. Institutional investors and hedge funds own 2.68% of the company’s stock.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.